Thierry Van Effelterre
Overview
Explore the profile of Thierry Van Effelterre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Curran D, de Ridder M, Van Effelterre T
Hum Vaccin Immunother
. 2016 Jul;
12(11):2765-2771.
PMID: 27428611
Hepatitis A vaccination stimulates memory cells to produce an anamnestic response. In this study, we used a mathematical model to examine how long-term immune memory might convey additional protection against...
12.
Taylor S, Ryser M, Mihalyi A, Van Effelterre T
Hum Vaccin Immunother
. 2016 May;
12(7):1943-6.
PMID: 27163545
No abstract available.
13.
Van Effelterre T, Dos Santos G, Shinde V
PLoS One
. 2016 Mar;
11(3):e0151575.
PMID: 27010830
Background: Vaccination campaigns against A/H1N1 2009 pandemic influenza virus (A/H1N1p) began in autumn 2009 in Europe, after the declaration of the pandemic at a global level. This study aimed to...
14.
Van Effelterre T, Marano C, Jacobsen K
Vaccine
. 2015 Dec;
34(4):555-562.
PMID: 26657185
Background: In most low- and middle-income countries, hepatitis A virus (HAV) is shifting or expected to shift from high endemicity to intermediate or low endemicity. A decreased risk of HAV...
15.
Hogea C, Van Effelterre T, Vyse A
Hum Vaccin Immunother
. 2015 Aug;
12(2):451-66.
PMID: 26308796
Various meningococcal conjugate vaccines exist against serogroups A, C, W and Y. A new protein-based vaccine targeting serogroup B (MenB) is also now available. The potential of such vaccines to...
16.
Hogea C, Dieussaert I, Van Effelterre T, Guignard A, Mols J
Hum Vaccin Immunother
. 2015 May;
11(7):1788-802.
PMID: 25984886
We present an age-structured dynamic transmission model for cytomegalovirus (CMV) in the United States, based on natural history and available data, primarily aiming to combine the available qualitative and quantitative...
17.
Van Effelterre T, Hogea C, Taylor S
Hum Vaccin Immunother
. 2014 Nov;
10(7):1794.
PMID: 25424784
We developed a dynamic compartmental model to assess the impact of HPV Universal Mass Vaccination with Cervarix(®), which offers protection against HPV16/18 and cross-protection against other cancer-causing types, using up-to-date...
18.
Phillips A, Cambiano V, Nakagawa F, Ford D, Lundgren J, Roset-Bahmanyar E, et al.
PLoS One
. 2014 Sep;
9(9):e107214.
PMID: 25207973
Background: It is important for public health and within the HIV vaccine development field to understand the potential population level impact of an HIV vaccine of partial efficacy--both in preventing...
19.
Hogea C, Van Effelterre T, Cassidy A
BMC Infect Dis
. 2014 Jun;
14:291.
PMID: 24884845
Background: Over the past decade, there has been sustained interest and efforts to develop a S. aureus vaccine. There is a need to better evaluate the potential public health impact...
20.
Pitzer V, Atkins K, Freiesleben De Blasio B, Van Effelterre T, Atchison C, Harris J, et al.
PLoS One
. 2012 Aug;
7(8):e42320.
PMID: 22912699
Early observations from countries that have introduced rotavirus vaccination suggest that there may be indirect protection for unvaccinated individuals, but it is unclear whether these benefits will extend to the...